ARINA-1 Clinical Trial UPDATE- (not an antibiotic)

ARINA-1 UPDATE: WE ARE MAKING A DIFFERENCE!

The good news is that the researchers have seen a significant increase in recruitment for the ARINA-1 trial.

ARINA-1 is a nebulized therapy (not an antibiotic) to treat mucus in bronchiectasis. The study is a 56-day study, with 28 days on therapy (ARINA-1 or placebo) and 28 days off therapy. It requires three study visits. This drug is designed to help improve our mucus symptoms and improve quality of life.

Click on the following link to clinicaltrials.gov for more information on the ARINA-1 trial.
https://tinyurl.com/ARINA-1-in-NCFBE
If you aren’t seen at one of the listed clinical trial sites, the sites are open to discussing if you qualify. There is also availability at sites for travel reimbursement. This is great news for us and an opportunity to participate in a trial, even if your treating center is not involved. The trial will close at the end of the year.

I am working with Renovion and researchers to share this opportunity, and I can help answer basic questions regarding:

Participating doctors
Laboratory studies of ARINA-1
How nebulizing this solution differs from nebulizing glutathione alone or orally administered NAC
The importance of the combination of glutathione and ascorbic acid

We have been asking for treatments for bronchiectasis that are not antibiotics. Participation in clinical trials is one way each one of us can impact drug development for our disease.

Let me know if you have any questions or ask your doctor.

These are exciting times,
Linda Esposito